PSA density lower cutoff value as a tool to exclude pathologic upstaging in initially diagnosed unilateral prostate cancer: Impact on hemiablative focal therapy

World Journal of Urology

Volumn 30, Issue 1, 2012, Pages 91-95

  Hofner, Thomas ^a   Pfitzenmaier, Jesco ^a   Alrabadi, Adel ^a   Pahernik, Sascha ^a   Hadaschik, Boris ^a   Wagener, Nina ^a   Djakovic, Nenad ^a   Haferkamp, Axel ^b   Hohenfellner, Markus ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Focal therapy; Prostate cancer; Prostate specific antigen density; Survival; Upstaging

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD; CANCER STAGING; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROSTATE; PROSTATE TUMOR; PROSTATECTOMY;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 84856224537     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-010-0631-6     Document Type: Article

References (25)

1. Mouraviev V, Mayes JM, Polascik TJ (2009) Pathologic basis of focal therapy for early-stage prostate cancer. Nat Rev Urol 6: 205-215.
2. Turkbey B, Pinto PA, Choyke PL (2009) Imaging techniques for prostate cancer: implications for focal therapy. Nat Rev Urol 6: 191-203.
3. Villers A, Lemaitre L, Haffner J, Puech P (2009) Current status of MRI for the diagnosis, staging and prognosis of prostate cancer: implications for focal therapy and active surveillance. Curr Opin Urol 19: 274-282.
4. Brassell SA, Kao TC, Sun L, Moul JW (2005) Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer. Urology 66: 1229-1233.
5. Magheli A, Hinz S, Hege C, Stephan C, Jung K, Miller K et al (2010) Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series: a single center experience. J Urol 183: 126-131.
6. Magheli A, Rais-Bahrami S, Trock BJ, Humphreys EB, Partin AW, Han M et al (2008) Prostate specific antigen versus prostate specific antigen density as a prognosticator of pathological characteristics and biochemical recurrence following radical prostatectomy. J Urol 179: 1780-1784 (discussion 4).
7. Frota R, Stein RJ, Turna B, Kamoi K, Lin YC, Magi-Galluzzi C et al (2009) Are prostate needle biopsies predictive of the laterality of significant cancer and positive surgical margins? BJU Int 104: 1599-1603.
8. Tareen B, Godoy G, Sankin A, Temkin S, Lepor H, Taneja SS (2009) Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer? BJU Int 104: 195-199.
9. Scales CD Jr, Presti JC Jr, Kane CJ, Terris MK, Aronson WJ, Amling CL et al (2007) Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy-results from the SEARCH database. J Urol 178: 1249-1252.
10. Mouraviev V, Mayes JM, Sun L, Madden JF, Moul JW, Polascik TJ (2007) Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer 110: 906-910.
11. Polascik TJ, Mayes JM, Schroeck FR, Sun L, Madden JF, Moul JW et al (2009) Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy. Cancer 115: 2104-2110.
12. Tareen B, Sankin A, Godoy G, Temkin S, Lepor H, Taneja SS (2009) Appropriate candidates for hemiablative focal therapy are infrequently encountered among men selected for radical prostatectomy in contemporary cohort. Urology 73: 351-354 (discussion 4-5).
13. Nogueira L, Wang L, Fine SW, Pinochet R, Kurta JM, Katz D et al (2010) Focal treatment or observation of prostate cancer: pretreatment accuracy of transrectal ultrasound biopsy and T2-weighted MRI. Urology 75: 472-477.
14. Wehbi E, Musquera M, Alcaraz A, Hanna S, Fleshner NE, Zlotta AR (2009) Focal therapy will be the future treatment modality: the motion "Con", update uro-oncology 2009, sixth fall meeting of the European Society of oncological urology (ESOU). Eur Urol Suppl 8: 433-438.
15. Conti SL, Dall'era M, Fradet V, Cowan JE, Simko J, Carroll PR (2009) Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol 181: 1628-1633 (discussion 33-34).
16. Dong F, Jones JS, Stephenson AJ, Magi-Galluzzi C, Reuther AM, Klein EA (2008) Prostate cancer volume at biopsy predicts clinically significant upgrading. J Urol 179: 896-900 (discussion).
17. Turley RS, Hamilton RJ, Terris MK, Kane CJ, Aronson WJ, Presti JC Jr et al (2008) Small transrectal ultrasound volume predicts clinically significant Gleason score upgrading after radical prostatectomy: results from the SEARCH database. J Urol 179: 523-527 (discussion 7-8).
18. Hong SK, Han BK, Lee ST, Kim SS, Min KE, Jeong SJ et al (2009) Prediction of Gleason score upgrading in low-risk prostate cancers diagnosed via multi (> or = 12)-core prostate biopsy. World J Urol 27: 271-276.
19. Postma R, de Vries SH, Roobol MJ, Wildhagen MF, Schroder FH, van der Kwast TH (2005) Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years. Cancer 103: 708-716.
20. Loeb S, Roehl KA, Thaxton CS, Catalona WJ (2008) Combined prostate-specific antigen density and biopsy features to predict "clinically insignificant" prostate cancer. Urology 72: 143-147.
21. Sajadi KP, Terris MK, Hamilton RJ, Cullen J, Amling CL, Kane CJ et al (2007) Body mass index, prostate weight and transrectal ultrasound prostate volume accuracy. J Urol 178: 990-995.
22. Sech S, Montoya J, Girman CJ, Rhodes T, Roehrborn CG (2001) Interexaminer reliability of transrectal ultrasound for estimating prostate volume. J Urol 166: 125-129.
23. Onik G, Miessau M, Bostwick DG (2009) Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J Clin Oncol 27: 4321-4326.
24. Patel AR, Jones JS (2009) Optimal biopsy strategies for the diagnosis and staging of prostate cancer. Curr Opin Urol 19: 232-237.
25. Abouassaly R, Lane BR, Jones JS (2008) Staging saturation biopsy in patients with prostate cancer on active surveillance protocol. Urology 71: 573-577.